Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Aug 12, 2022 8:40am
152 Views
Post# 34890832

RE:RE:Q2 CC snapshot

RE:RE:Q2 CC snapshot
gudisgood wrote:

Good summary - thanks Mugsy!

Any thoughts on zero buybacks in July and August (so far)?

The market seemed to like Q2... nobody knows how these will work out, but there's a fair chance we'll have some disappointment in Q3 or Q4 due to reasons you mentioned: mainly the Gileard portfolio and Exelon channel sales. Or perhaps not! Who knows. :)

On the other hand, we get to take over Exelon marketing, we have growing products, we have our salesforce out there, Akynzeo bringing in some money...

Also good to note that since they're terminating the Gilead deal, it probably added very little to the bottom line? So even though revenue takes a hit, profits will likely not.

Samira stayed on the Paladin question for a while (could have only said that they're always opportunistic). They're definitely paying attention to how that unfolds. It was interesting to hear that they prioritize Mexico and Canada when looking at deals (which are "suboptimal" right now).


Thoughts ...

Buybacks will happen in a certain range and that range might get adjusted based on perceived value.  There could be a period where less attention is paid to buybacks and more on other opportunities.

It is possible that filling the pipeline for Exelon will have a positive effect but I would expect a weaker last two quarters after that - just keeping in tune with expected full year revenue numbers.

Agree with what you are saying about the value of the Gilead deal - might not play on the bottom line.  Sure hope that's the case.

Mexico and Canada - does need some beefing up.  I know M8 was on her list of interests and they're probably looking at M8 similars in Mexico.  Wonder where that $100M financing stands and if M8/GUD would ever make that a reality.

As we know - nothing happens quickly.  Hahaha !
<< Previous
Bullboard Posts
Next >>